These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 21190184)

  • 1. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
    Eisenhardt AE; Olbrich H; Röring M; Janzarik W; Anh TN; Cin H; Remke M; Witt H; Korshunov A; Pfister SM; Omran H; Brummer T
    Int J Cancer; 2011 Nov; 129(9):2297-303. PubMed ID: 21190184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
    Cin H; Meyer C; Herr R; Janzarik WG; Lambert S; Jones DT; Jacob K; Benner A; Witt H; Remke M; Bender S; Falkenstein F; Van Anh TN; Olbrich H; von Deimling A; Pekrun A; Kulozik AE; Gnekow A; Scheurlen W; Witt O; Omran H; Jabado N; Collins VP; Brummer T; Marschalek R; Lichter P; Korshunov A; Pfister SM
    Acta Neuropathol; 2011 Jun; 121(6):763-74. PubMed ID: 21424530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas.
    Jacob K; Quang-Khuong DA; Jones DT; Witt H; Lambert S; Albrecht S; Witt O; Vezina C; Shirinian M; Faury D; Garami M; Hauser P; Klekner A; Bognar L; Farmer JP; Montes JL; Atkinson J; Hawkins C; Korshunov A; Collins VP; Pfister SM; Tabori U; Jabado N
    Clin Cancer Res; 2011 Jul; 17(14):4650-60. PubMed ID: 21610151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior.
    Bannykh SI; Mirocha J; Nuno M; Lopategui J; Kandala G
    Clin Neuropathol; 2014; 33(6):388-98. PubMed ID: 25066317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.
    Kotoula V; Sozopoulos E; Litsiou H; Fanourakis G; Koletsa T; Voutsinas G; Tseleni-Balafouta S; Mitsiades CS; Wellmann A; Mitsiades N
    Endocr Relat Cancer; 2009 Jun; 16(2):565-72. PubMed ID: 19190079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.
    Brummer T; Martin P; Herzog S; Misawa Y; Daly RJ; Reth M
    Oncogene; 2006 Oct; 25(47):6262-76. PubMed ID: 16702958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma.
    Pathak P; Kumar A; Jha P; Purkait S; Faruq M; Suri A; Suri V; Sharma MC; Sarkar C
    Brain Pathol; 2017 Sep; 27(5):580-589. PubMed ID: 27608415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
    Andreadi C; Cheung LK; Giblett S; Patel B; Jin H; Mercer K; Kamata T; Lee P; Williams A; McMahon M; Marais R; Pritchard C
    Genes Dev; 2012 Sep; 26(17):1945-58. PubMed ID: 22892241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation.
    Heard JJ; Phung I; Potes MI; Tamanoi F
    BMC Cancer; 2018 Jan; 18(1):69. PubMed ID: 29320991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recurrent somatic BRAF insertion (p.V504_R506dup): a tumor marker and a potential therapeutic target in pilocytic astrocytoma.
    Khater F; Langlois S; Cassart P; Roy AM; Lajoie M; Healy J; Richer C; St-Onge P; Piché N; Perreault S; Cellot S; Marzouki M; Jabado N; Sinnett D
    Oncogene; 2019 Apr; 38(16):2994-3002. PubMed ID: 30575814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma.
    Bar EE; Lin A; Tihan T; Burger PC; Eberhart CG
    J Neuropathol Exp Neurol; 2008 Sep; 67(9):878-87. PubMed ID: 18716556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult with cerebellar anaplastic pilocytic astrocytoma associated with BRAF V600E mutation and p16 loss.
    Yeo YH; Byrne NP; Counelis GJ; Perry A
    Clin Neuropathol; 2013; 32(3):159-64. PubMed ID: 23196000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilocytic astrocytoma: a disease with evolving molecular heterogeneity.
    Sadighi Z; Slopis J
    J Child Neurol; 2013 May; 28(5):625-32. PubMed ID: 23439714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma.
    Tomić TT; Olausson J; Wilzén A; Sabel M; Truvé K; Sjögren H; Dósa S; Tisell M; Lannering B; Enlund F; Martinsson T; Åman P; Abel F
    PLoS One; 2017; 12(4):e0175638. PubMed ID: 28448514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF alterations in primary brain tumors.
    Maraka S; Janku F
    Discov Med; 2018 Aug; 26(141):51-60. PubMed ID: 30265855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.
    Jones DT; Kocialkowski S; Liu L; Pearson DM; Ichimura K; Collins VP
    Oncogene; 2009 May; 28(20):2119-23. PubMed ID: 19363522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.